Medexus Pharmaceuticals Inc. (TSX:MDP)

Medexus Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	103.3	99.33	108.33	113.05	108.1	76.7
Revenue Growth	-2.23%	-8.31%	-4.18%	4.59%	40.93%	-3.72%
Gross Profit Gross Profit Growth	65.97	63.86	63.51	65.07	65.77	43.67
Operating Income Operating Income Growth	7.1	5.84	11.92	12.79	8.49	-12.38
Net Income Net Income Growth	-2.37	-2.39	2.25	-0.21	1.22	-2.88
Earnings Per Share EPS Growth	-0.07	-0.07	0.08	-0.01	0.06	-0.15
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
United States United States Growth	74.74	74.74	68.61	77.18	78.94	52.01
Canada Canada Growth	24.59	24.59	39.72	35.87	29.16	24.7
Total Total Growth	99.33	99.33	108.33	113.05	108.1	76.7

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	5.34	6.52	23.97	5.26	13.07	10.02
Total Debt Total Debt Growth	26.25	22.26	37.18	49.9	70.08	54.86
Net Cash (Debt) Net Cash Growth	-20.91	-15.74	-13.21	-44.64	-57.01	-44.84
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-0.65	-0.49	-0.50	-2.00	-2.78	-2.26

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	14.23	18.87	24.03	18.71	-1.44	-1.18
Capital Expenditures CapEx Growth	-0.05	-0.15	-0.18	-0.05	-0.06	-0.1
Free Cash Flow Free Cash Flow Growth	14.18	18.72	23.85	18.66	-1.51	-1.28
Free Cash Flow Growth	-27.24%	-21.51%	27.79%	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	63.86%	64.29%	58.62%	57.56%	60.84%	56.94%
Operating Margin	6.87%	5.87%	11.00%	11.31%	7.85%	-16.13%
Pretax Margin	-2.31%	-2.29%	1.33%	0.09%	-4.66%	-4.98%
Profit Margin	-2.29%	-2.41%	2.07%	-0.19%	1.13%	-3.75%
FCF Margin	13.72%	18.85%	22.02%	16.51%	-1.39%	-1.67%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 11, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	-	-	24.17	-	19.55	-
Forward PE	12.30	7.48	19.63	5.21	43.87	43.87
P/FCF Ratio	6.13	3.85	2.28	1.56	-	-
PS Ratio	1.16	0.73	0.50	0.26	0.22	0.65

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error